Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Buys Alzheimer’s Disease Research Data From TorreyPines

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai said Nov. 11 it signed an agreement with California-based TorreyPines Therapeutics to purchase all research data and assets from TorreyPines' research activities on genes associated with late-onset Alzheimer's disease for an undisclosed upfront payment

You may also be interested in...

Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 1 Of 2)

TOKYO - Swedish startup BioArctic Neuroscience CEO Pär Gellerfors wondered who was calling him at 8 a.m. one June morning back in 2003.

Rethinking Alzheimer's: Mapping Out an Approval Process

Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts